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Abstract
Background Polypharmacy, i.e. the simultaneous use of
multiple drugs, is known to be associated with compliance
errors and adverse drug reactions. Norway has a list-patient
system in general practice, formalizing the relationship
between the patient and his/her regular general practitioner
(GP). One important aim with a list-patient system is to
secure medical quality in primary care by giving the GP the
responsibility for coordinating the medical treatment.
Objective To examine the regular GP’s role in
polypharmacy to the home-dwelling elderly in Norway and
to determine by how much multiple prescribers increase
the risk of polypharmacy.
Methods This was a population registry study based on
data on all prescription drugs dispensed at pharmacies to
patients 70 years and older from the Norwegian Prescrip-
tion Database, merged with data on GPs and GPs’ patient
lists from the Regular General Practitioner Database. The
dataset included 624,308 patients and 4520 GPs in the
period from 2004 to 2007. Outcome measures were:
number of drug-substances prescribed and dispensed per
patient by the regular GP, other GPs, non-GP specialists
and hospital doctors; polypharmacy, defined as five or
more prescribed and dispensed substances in the same
quarter; excessive polypharmacy, defined as ten or more
prescribed and dispensed substances in the same quarter.
Results Polypharmacy is high and increasing despite the
list-patient system. GPs prescribe all the substances that
cause polypharmacy in 64 % of the incidents, but the
patients’ risk of polypharmacy increases substantially with
number of prescribers, odds ratio 2.32 (95 % CI 2.31–2.33).
Conclusion GPs have a major role in the high and
increasing polypharmacy among the elderly in Norway.
Any intervention intending to improve the situation must
necessarily include the GPs.
Key Points
Prescriptions from the patient’s regular GP
contribute to the bulk of polypharmacy among the
elderly.
Despite a list-patient system in general practice,
polypharmacy increases over time.
Patients’ risk of polypharmacy increases with the
number of prescribers.
1 Introduction
Polypharmacy, i.e. the simultaneous use of multiple drugs,
is known to be associated with compliance errors and
adverse drug reactions [1]. Since multi-morbidity is com-
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specialists from different fields is often required [3, 4].
Both the increasing morbidity and the change in the human
body with age make adverse drug reactions more likely
among the elderly [3–6]. The risk of drug interactions and
the probability of compliance errors increases with the
quantity of drugs and substances used [7–9]. The number
of drug substances is shown to be the most important
clinical predictor of adverse drug reactions [10]. A study
from Norway indicated that one-third of the elderly Nor-
wegian population is exposed to potentially inappropriate
medications [11]. The number of prescribing physicians
may be an independent risk factor for adverse drug reac-
tions [12], and studies also reveal a large variation in
physicians’ individual prescription practice, not least in
terms of polypharmacy [13].
Norway has a list-patient system in general practice for-
malizing the relationship between the patient and his/her reg-
ular general practitioner (GP). One important aim with a list-
patient system is to secure medical quality in primary care by
giving the GP the responsibility for coordinating the medical
treatment [14] which gives the GP a unique ‘spider-in-the-
web’ position. The patient may, however, use another GP with
whom he/she is not registered during holidays or when no
appointments are available for other reasons. The GPs are
gatekeepers to specialist health care. Hence, patients generally
need a referral from their GP to see a medical specialist.
The aim of this study is to explore the role of the patient’s
regular GP in a list patient system, with a special reference to
polypharmacy. The main issues addressed are: (a) what
proportion of multiple drugs and drug substances are pre-
scribed by the patient’s regular GP? and (b) does the number
of prescribers for the same patient predict polypharmacy?
2 Methods
2.1 Setting and Participants
Data from the Norwegian Prescription Database (NorPD)
of all prescription drugs dispensed at pharmacies to the
home-dwelling elderly (C70 years old) were merged with
data on GPs and their patient lists from the Regular General
Practitioner Database (RPD).
2.2 Collected Data
Data from the NorPD are based on electronic registration
of every prescription collected at pharmacies in Norway.
NorPD is a state-run registry and all pharmacies are com-
pelled to register all their prescriptions as they are expe-
dited. We were given access to the total registry covering
the years 2004–2007. Patients and prescribers are given a
unique code in the registry which allows prescriptions by
the same prescriber as well as prescriptions to one single
patient to be followed over time.
For each of the included patients, the medication pre-
scribed by the regular GP, by other GPs and by non-GP
specialists and hospital doctors were calculated separately.
The variables of interest were aggregated over quarters.
Other GPs are identified as GPs that are found in the RPD
database at the time the drugs were dispensed, but are not
the patient’s regular GP. Non-GP specialists and hospital
doctors are identified by not being in the RPD database at
the time of dispensing the medication, but registered as a
physician in the NorPD database. The methods have pre-
viously been described in more detail [15].
2.3 Outcomes
Outcomes were: the number of different drug-substances
prescribed and dispensed to a patient in the same quarter;
the presence of polypharmacy, defined as five or more drug
substances prescribed and dispensed to a patient in the
same quarter; and presence of excessive polypharmacy,
defined as ten or more drug substances prescribed and
dispensed to a patient in the same quarter.
The use of five or more substances is a standard cut-off
for clinically relevant polypharmacy, while the concurrent
use of ten or more substances has been suggested to rep-
resent excessive polypharmacy [13].
The classification of drug-substances is based on the
Anatomical Therapeutic Chemical (ATC) classification
system, in which a drug-substance is defined at the highest
level, using all elements in the classification system from
WHO [16].
2.4 Statistics and Analytical Procedures
Since our dataset covers the whole population of the
elderly (70 years and older), descriptive statistics are pre-
sented as actually observed values and means without
confidence intervals (CIs). In regression analysis, 95 % CIs
are presented.
A multiple logistic regression was performed to calcu-
late the association between number of prescribers and
polypharmacy, confounders were age and gender. All
analyses were conducted in STATA version 10 (Stata Corp
LP, College Station, TX, USA).
3 Results
3.1 Population
The dataset consisted of 624,308 patients, listed with 4520
GPs over 4 years, giving 7,958,068 quarterly patient
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observations. A total of 41 million prescriptions were
registered over the observation period.
3.2 The GPs’ Share of Prescribed Drug Substances
The regular GP prescribed 69 % of the drug-substances,
while 9 % were prescribed by other GPs, and 22 % by non-
GP specialists and hospital doctors.
The number of drugs per patient is on average 3.6 per
quarter (Table 1).
3.3 The Development of Polypharmacy
In 2007, the fraction of elderly patients that received at
least five drug substances quarterly (polypharmacy) was
36 % (176,626 of 497,538 individuals), while 7 % (32,340
of 497,538 individuals) received at least ten drug sub-
stances quarterly (excessive polypharmacy).
Further, in 2007 the GP was responsible for more than
64 % (113,439 of 176,626) of polypharmacy incidents and
40 % (12,936 of 32,340) of excessive polypharmacy inci-
dents (Table 2). The GPs’ proportion has increased steadily
from 2004 (Fig. 1).
Table 3 shows the results of logistic regression analyses
estimating the risk of polypharmacy and excessive
polypharmacy with increasing number of prescribers.
Number of prescribers was strongly predictive of
polypharmacy and excessive polypharmacy (OR 2.32). A
positive time trend as well as seasonal variation was
observed in both regressions (Fig. 1). The seasonal
dummies show that the risk of polypharmacy is lowest in
the first quarter, and 40 % higher in the fourth quarter.
Patient age and gender were also significant predictors.
4 Discussion
4.1 Summary of Main Findings
We have shown that the home-dwelling elderly in Norway
received a high and increasing number of drug substances
between 2004 and 2007. Over this period, polypharmacy
and excessive polypharmacy was observed among a mean
of 33 and 6 % of the patients, respectively. It increased
steadily over time. The GP was responsible for 63 % of the
polypharmacy incidents and 39 % of the excessive
polypharmacy incidents. Since the GPs prescribe most of
the drugs, polypharmacy caused by the regular GP is fre-
quent. The number of prescribing physicians per patient
increased the patients’ risk of polypharmacy; increasing the
number of prescribers by one more than doubled the risk of
polypharmacy.
4.2 Strengths and Limitations
The data explored in this study are extracted from a registry
of all prescriptions dispensed to the total populations of the
home-dwelling elderly in Norway as opposed to prescrip-
tions prescribed. Since compliance with prescriptions is a
well-known problem [8], this is a considerable strength.
Table 1 Average quarterly
number of drug substances per
patient, by physician group
(N = 7,958,068)
2004 2005 2006 2007 Overall mean
Number of drug substances
From the regular GP 2.3 2.4 2.5 2.6 2.5
From another GP 0.3 0.3 0.3 0.3 0.3
From non-GP specialists and hospital doctors 0.7 0.8 0.8 0.8 0.8
Total 3.4 3.5 3.6 3.8 3.6
GP general practitioner
Table 2 Development in the number of patients experiencing polypharmacy and major polypharmacy
2004 2005 2006 2007 Overall mean % change 2004–2007
Polypharmacy 152,778 161,851 168,774 176,626 164,632 16
No. of these prescribed by the GP 95,548 102,274 107,039 113,439 104,450 19
Excessive polypharmacy 24,882 27,306 29,374 32,340 28,351 30
No. of these prescribed by the GP 8958 10,426 11,451 12,936 10,942 44
N 497,648 496,475 497,857 497,538 497,379 0
Polypharmacy from the GP ( %) 63 63 63 64 63 3
Excessive polypharmacy from the GP ( %) 36 38 39 40 39 11
GP general practitioner
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Two phenomena may contribute to underestimation of
polypharmacy in our dataset. First, GPs in Norway are not
obliged to report to the health authorities when patients
move into an institution and receive drugs directly from the
institution, and, second, the patients’ use of over-the-
counter drugs is not registered in the database. Thus our
data may underestimate the actual drug use, which serves
to strengthen the significance of our results as an even
higher medication use may be expected if this non-regis-
tered data could have been included. However, the esti-
mated size of the population moving into an institution,
based on official statistics, suggests this at most to repre-
sent 8 % of the elderly.
Our indicator of polypharmacy is drugs purchased
within a 3-month period. Bjerrum et al. [9] conclude that
from a conceptual point of view, an estimator based on the
number of simultaneously used drugs (calculated from the
date of purchase) is preferable, but also that the number of
drugs purchased in a 3-month period may be a useful
estimator. The advantage with this simple and robust
measure is that it can be used to compare seasonal differ-
ences in the purchasing of drugs.
Factors related to the patient’s health and diagnoses, and
factors related to the accessibility of high-quality health-
care provision may explain part of the increase in
polypharmacy over time. We cannot address these issues
through a prescription registry with no medical information
other than the prescription itself.
4.3 Discussion of the Results
On average patients received 3.6 drugs quarterly. In a study
from Denmark of 75-year-olds living in their own homes,
the average number of medications per patient was 4.4,
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Fig. 1 Time trends of the
presence of polypharmacy and
excessive polypharmacy as well
as polypharmacy incidents and
excessive polypharmacy
incidents prescribed by the
general practitioner (GP) alone
over the observation period.
Prescription in 2004 was set as
the starting point within each
category
Table 3 Logistic regression.
Number of prescribers, season
prescribed, and age and gender
influences on patients’ odds for
polypharmacy and excessive
polypharmacy (odds ratios for
physicians and time are age- and
gender-adjusted)
Polypharmacy Excessive polypharmacy
Odds ratio P value 95 % CI Odds ratio P value 95 % CI
Number of physicians 2.323 \0.001 2.316–2.331 1.987 \0.001 1.978–1.997
Time trend 1.078 \0.001 1.076–1.080 1.122 \0.001 1.118–1.127
Season prescribed with first quarter as reference
Quarter 2 1.176 \0.001 1.171–1.181 1.153 \0.001 1.142–1.164
Quarter 3 1.110 \0.001 1.105–1.115 1.083 \0.001 1.072–1.093
Quarter 4 1.405 \0.001 1.399–1.412 1.433 \0.001 1.419–1.446
Patient age 1.024 \0.001 1.023–1.025 1.025 \0.001 1.023–1.026
Patient gender 1.135 \0.001 1.123–1.147 1.158 \0.001 1.138–1.178
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The average number of medicines prescribed for people
aged 60 years and over in England has almost doubled per
person per year over the past decade [17]. This represents a
yearly increase of nearly 7 %. In comparison the yearly
increase of average amounts per patient in our data is 4 %.
A high level and a trend towards increasing polyphar-
macy among the elderly which we have documented here
may also reflect an increasing complexity of highly spe-
cialised medical treatment. However, the number of pre-
scribed drugs has also been shown to be one of the most
important predictors of adverse drug reactions [1, 10], and
the elderly are more sensitive to side effects as well as
having less metabolic capacity for eliminating excess drugs
[3–6]. We therefore suggest that the results described here
are worrying and deserve further focus. The finding that the
segment with the highest number of drugs (excessive
polypharmacy) increases most rapidly supports this.
The risk of polypharmacy increased with the number of
prescribers. Thus, a special awareness among GPs toward
their patients is needed when many physicians are
involved, in order to prevent dangerous combinations. This
is of special importance in the presence of complicated
illness and multiple co-morbid conditions where more
prescribers are likely to be involved. The importance of
adequate communication between different physicians is
thus also highlighted.
The seasonal difference in polypharmacy is worth not-
ing. The risk is lowest in the first quarter and highest in the
fourth. In Norway patients are reimbursed for the cost of
drugs when accumulated costs exceed a certain threshold
during one calendar year. Thus, in the last quarter of the
year many elderly people may stock up drugs because they
are more likely to have reached the reimbursement
threshold. Knowing that compliance errors are common in
the elderly population [3], this may represent a health risk
and is thus an example of the direct influence of health
economic policies regarding medication reimbursement on
prescription-related risk.
Though less frequent, polypharmacy also occurs in the
group of patients who received medications only from their
regular GP. This finding suggests that the polypharmacy
problem needs to be attended to both by measures
addressed towards the quality of drug prescriptions by the
regular GPs, and by measures improving communication
and coordination between different prescribers. We have
previously showed that there is a relationship between the
number of prescribers and the prescription of addictive
medication [15]; polypharmacy may further complete this
pattern.
The relationship between the number of prescribers and
the number of drugs prescribed is important and justifies
the idea of having one physician, e.g. the GP, as the
‘controlling agent’, with the task of being observant of the
risk of, and trying to reduce, such polypharmacy and its
negative consequences. However, as the regular GP him-/
herself also contributes importantly to polypharmacy, an
increased general awareness of the problem and its con-
sequences among GPs as well as a focus on the practice
situation and logistics which may influence prescribing is
required. By necessity this requires GPs well trained in
clinical pharmacology among the elderly as well as sys-
tems supporting GPs in their handling of ever-more spe-
cialised medical treatment prescribed by various other
specialists.
5 Conclusion
The results indicate that the Norwegian list-patient system
does not prevent polypharmacy, nor does it prevent an
increase in polypharmacy over time. More research is
needed to explore the main reasons for the demonstrated
frequent and increasing polypharmacy. However, it is clear
that no change in prescription practices regarding
polypharmacy can be undertaken without involvement of
GPs.
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